- Pelthos Therapeutics acquired U.S. commercialization rights to Xepi (ozenoxacin) cream, the first new impetigo treatment approved in over 10 years, addressing critical antibiotic resistance issues. - The FDA-approved topical antimicrobial targets impetigo caused by Staphylococcus aureus and Streptococcus pyogenes, affecting approximately 3 million Americans annually, primarily children ages 2-5. - The company secured $18 million in convertible notes financing to support Xepi's re-launch in late 2026 and accelerate commercialization of its molluscum contagiosum treatment ZELSUVMI. - Xepi represents a significant therapeutic advancement as one of few treatments effective against both methicillin-resistant and mupirocin-resistant Staphylococcus aureus infections.

Nov 8, 2025

返回机构列表

Ferrer Internacional S.A.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（62）

Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

药物批准

按机构分类的批准

近期批准

资讯

Pelthos Therapeutics Acquires Xepi for Antibiotic-Resistant Impetigo Treatment and Secures $18 Million Financing